Active Pharmaceutical Ingredients
Dutasteride IR (Immediate Release) Pellets are specialized oral solid dosage forms designed for rapid release of Dutasteride, a dual 5-alpha reductase inhibitor. These pellets ensure quick dissolution and absorption, offering effective treatment for benign prostatic hyperplasia (BPH) and other related conditions where fast drug action is required.
| Component | Function |
|---|---|
| Dutasteride | Active Pharmaceutical Ingredient (API) |
| Sugar Spheres / MCC Spheres | Inert core or starter pellets |
| Hydroxypropyl Methylcellulose (HPMC) | Binder / Film former during layering |
| Talc / Colloidal Silicon Dioxide | Anti-adherent / Glidant |
| Ethylcellulose / Eudragit RS/RL | Sustained release polymer (controls drug release) |
| Triethyl Citrate / PEG 6000 | Plasticizer (for polymer coating) |
| Purified Water | Solvent (removed after processing) |
Outsourcing pellets through a trusted partner like Salius Pharma can be a strategic decision to save both time and resources, without compromising on quality or compliance. Instead, partnering with Salius Pharma—a leading distributor aligned with USFDA-approved and WHO-GMP-certified manufacturers in India—allows you to leverage high-quality products, seamless logistics, and professional support under one roof.
We ensure prompt and reliable shipping worldwide. Delivery times may vary depending on destination, order volume, and regulatory requirements.
Looking to source Dutasteride IR Pellets or other high-quality pharmaceutical pellet formulations?
Whether you need Active Pharmaceutical Ingredients (APIs), excipients, or regulatory support, our team is ready to provide reliable, compliant, and cost-effective solutions tailored to your market needs.
The contents of this page and any attachments are intended solely for the designated recipient(s) and may contain confidential and/or privileged information protected by law.
Any patented products are excluded from our offerings in regions where such patents are currently in force.
They are primarily used for the management of benign prostatic hyperplasia (BPH), helping reduce prostate size and improve urinary flow.
The uniform size distribution of pellets improves dissolution, reduces variability in absorption, and enhances overall bioavailability compared to conventional dosage forms.
They provide a uniform, inert substrate that ensures consistent layering of the API and improved reproducibility during large-scale manufacturing.
We provide COA (Certificate of Analysis), MSDS (Material Safety Data Sheet), Stability Data, and necessary regulatory support documents.